Claims:

1. A compound of formula I,

$$R^1$$
-OP(O)(OH)₂

- wherein R¹ represents the non-hydroxy portion of a triazole antifungal compound of the type comprising a tertiary hydroxy group; or a pharmaceutically acceptable salt thereof.
 - 2. A compound as claimed in claim 1, wherein R¹ is a group of formula la,

$$\begin{array}{c|c} R^3 & & Ia \\ \hline \\ N & R^2 & & \end{array}$$

10 in which

30

R² represents phenyl substituted by one or more halogen atoms;

R³ represents H or CH₃;

R^{3a} represents H, or together with R³ it may represent =CH₂; and

R⁴ represents a 5- or 6-membered nitrogen-containing heterocyclic ring which is optionally substituted by one or more groups selected from halogen, =0, phenyl [substituted by a group selected from CN and (C₆H₄)-OCH₂CF₂CHF₂] or CH=CH-(C₆H₄)-OCH₂CF₂CHF₂; or phenyl substituted by one or more groups selected from halogen and methylpyrazolyl.

- 3. A compound as claimed in claim 2, wherein R² is 2,4-difluorophenyl.
- 20 4. A compound as claimed in claim 2 or claim 3, wherein R³ is H or methyl.
 - 5. A compound as claimed in any one of claims 2 to 4, wherein R⁴ represents or comprises a triazolyl, pyrimidinyl or thiazolyl group.
 - 6. A compound as claimed in any one of the preceding claims, which is: 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propyl dihydrogen phosphate; or
- 25 (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butyl dihydrogen phosphate;

or a pharmaceutically acceptable salt thereof.

- 7. A pharmaceutical formulation comprising a compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
- 8. A compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical.

- 9. The use of a compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of fungal infections.
- 10. A method of treatment or prevention of fungal infections, which comprises administering a compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment.
 - 11. A process for the production of a compound of formula I, as defined in claim 1, or a pharmaceutically acceptable salt thereof, which comprises phosphorylating a compound of formula II,

10 R¹OH II

wherein R¹ is as defined in claim 1;

and where desired or necessary converting the resulting compound into a pharmaceutically acceptable salt or vice versa.

12. A process as claimed in claim 11, which comprises the step of removing the hydroxy protecting groups from a compound of formula V,

 R^1 -OP(O)(OR°)(OR^d) V

wherein R^1 is as defined in claim 1, and R^c and R^d independently represent hydroxy protecting groups.

- 13. The process as claimed in claim 12, wherein R^c and R^d independently represent
 20 benzyl optionally substituted by one or more halogen atoms.
 - 14. A compound of formula V, as defined in claim 12.
 - 15. A method of improving the aqueous solubility of a triazole antifungal compound of the type comprising a tertiary hydroxy group, which comprises converting the tertiary hydroxy group into a phosphate group, or a pharmaceutically acceptable salt thereof.